Abstract:As a neurobiological process, addiction involves pathological patterns of engagement with substances and a range of behaviors with a chronic and relapsing course. Neuroimaging technologies assess brain activity, structure, physiology, and metabolism at scales ranging from neurotransmitter receptors to large-scale brain networks, providing unique windows into the core neural processes implicated in substance use disorders. Identified aberrations in the neural substrates of reward and salience processing, response inhibition, interoception, and executive functions with neuroimaging can inform the development of pharmacological, neuromodulatory, and psychotherapeutic interventions to modulate the disordered neurobiology. Based on our systematic search, 409 protocols registered on ClinicalTrials.gov include the use of one or more neuroimaging paradigms as an outcome measure in addiction, with the majority (N=268) employing functional magnetic resonance imaging (fMRI), followed by positron emission tomography (PET) (N=71), electroencephalography (EEG) (N=50), structural magnetic resonance imaging (MRI) (N=35) and magnetic resonance spectroscopy (MRS) (N=35). Furthermore, in a PubMed systematic review, we identified 61 meta-analyses including 30 fMRI, 22 structural MRI, 8 EEG, 7 PET, and 3 MRS meta-analyses suggesting potential biomarkers in addictions. These studies can facilitate the development of a range of biomarkers that may prove useful in the arsenal of addiction treatments in the coming years. There is evidence that these markers of large-scale brain structure and activity may indicate vulnerability or separate disease subtypes, predict response to treatment, or provide objective measures of treatment response or recovery. Neuroimaging biomarkers can also suggest novel targets for interventions. Closed or open loop interventions can integrate these biomarkers with neuromodulation in real-time or offline to personalize stimulation parameters and deliver the precise intervention. This review provides an overview of neuroimaging modalities in addiction, potential neuroimaging biomarkers, and their physiologic and clinical relevance. Future directions and challenges in bringing these putative biomarkers from the bench to the bedside are also discussed.

Neuroscience of drug craving for addiction medicine: From circuits to therapies

The distribution of neurotransmitters in the brain circuitry: Mesolimbic pathway and addiction

Preventing incubation of drug craving to treat drug relapse: from bench to bedside

Network state dynamics underpin craving in a transdiagnostic population

Connectome-based prediction of craving in gambling disorder and cocaine use disorder

Network state dynamics underpin basal craving in a transdiagnostic population

Neurobiological mechanisms and related clinical treatment of addiction: a review

Neuroscience of Drugs and Addiction

Temporal Dynamics of Neural Response to Drug Cues in abstinent Methamphetamine Users

Current Progresses in Drug Addiction Theories

Heroin addiction hijacks the Nucleus Accumbens: craving and reactivity to naturalistic stimuli

Drug abuse: hedonic homeostatic dysregulation.

Neurobiological Mechanisms and Interventions in Drug Craving after Withdrawal

Prediction of craving across studies: A commentary on conceptual and methodological considerations when using data-driven methods

Compulsive Drug-Taking is Associated with Habenula–frontal Cortex Connectivity

Neural Systems of Reinforcement for Drug Addiction: from Actions to Habits to Compulsion

Neuroimaging Biomarkers in Addiction

The Neuropsychological Basis of Addictive Behaviour

Reward circuitry dopaminergic activation regulates food and drug craving behavior

Craving to quit: Psychological models and neurobiological mechanisms of mindfulness training as treatment for addictions.